Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.62 |
| ▸ | ITGAV | P06756 | 17/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845065 | 0.97 | ITGB3 (0.59) | ITGB3ITGAVHTTSMN1; SMN2ITGA2B | |
| SCHEMBL5845136 | 0.92 | ITGB3 (0.55) | ITGB3ITGAVHTTSMN1; SMN2ITGA2B | |
| SCHEMBL7168552 | 0.83 | ITGB3 (0.62) | ITGB3ITGAVSMN1; SMN2ITGA2BITGB5 | |
| SCHEMBL2037116 | 0.81 | ITGB3 (0.70) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL5844128 | 0.80 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL4717622 | 0.80 | ITGB3 (0.68) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL4398060 | 0.80 | ITGB3 (0.68) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL5846620 | 0.79 | ITGB3 (0.69) | ITGB3ITGAVITGA2BITGB5ITGB6 | |
| SCHEMBL4394126 | 0.79 | ITGB3 (0.64) | ITGB3ITGAVSMN1; SMN2ITGA2BITGB5 | |
| SCHEMBL5843924 | 0.79 | ITGAV (0.82) | ITGB3ITGAVITGA2BITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135587-B2 | Urea and urethane derivatives as integrin inhibitors | MERCK PATENT GMBH (DE) | 2006-11-14 | — | — | US | disclosed |
| EP-1343764-B1 | UREA AND URETHANE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2004-08-25 | — | — | EP | disclosed |
| US-20040063644-A1 | Urea and urethane derivatives as integrin inhibitors | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| EP-1343764-A1 | UREA AND URETHANE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GmbH (DE) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050039-A1 | UREA AND URETHANE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063644-A1 | Urea and urethane derivatives as integrin inhibitors | ITGB1, ITGB2, ITGA1 | ITGB3 7/4885ITGAV 16/4885HTT 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.